Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/5/2025

Urologic Workup and Treatment for Chronic Urinary Tract Infections (UTIs)

Diagnostic Evaluation

  • The European Urology guidelines recommend confirming recurrent UTI diagnosis via urine culture before initiating treatment to guide appropriate therapy 1, 3
  • For women under 40 years with no risk factors, extensive routine workup (cystoscopy, full abdominal ultrasound) is not recommended 1, 2
  • For patients with persistent fever after 72 hours of treatment or clinical deterioration, consider contrast-enhanced CT scan or excretory urography 1
  • Evaluation of upper urinary tract via ultrasound should be performed in patients with high urine pH 1

Risk Factors Assessment

  • Recognize that recurrent UTIs significantly impact quality of life, affecting social and sexual relationships, self-esteem, and work capacity 2
  • For postmenopausal women, assess for high postvoid residual urine volume 2, 3

Treatment Approach

First-line Treatment for Acute Episodes

  • For uncomplicated cystitis in women, the European Urology guidelines recommend Fosfomycin trometamol 3g single dose, or Nitrofurantoin macrocrystals 50-100mg four times daily for 5 days, or Nitrofurantoin monohydrate/macrocrystals 100mg twice daily for 5 days, or Pivmecillinam 400mg three times daily for 3-5 days 1, 2
  • For men with UTI, the European Urology guidelines recommend Trimethoprim-sulfamethoxazole 160/800mg twice daily for 7 days (if local resistance patterns permit) 1, 2
  • Fluoroquinolones can be prescribed based on local susceptibility testing 1, 2

Prevention Strategies for Recurrent UTIs

  • The European Urology guidelines recommend non-pharmacological measures, such as advising premenopausal women to increase fluid intake 1, 2
  • Counsel regarding avoidance of risk factors 1, 2
  • For postmenopausal women, vaginal estrogen replacement is recommended (strong recommendation) 1, 2, 3
  • Immunoactive prophylaxis for all age groups is recommended (strong recommendation) 1, 2, 3
  • Methenamine hippurate for women without urinary tract abnormalities is recommended (strong recommendation) 1, 2, 3

Treatment Pitfalls to Avoid

  • Avoid fluoroquinolones as first-line empiric therapy due to increasing resistance and adverse effects 3